Antoni Ribas

Oncology · 2010–2022

A researcher in the Science corpus: 49 papers; trusts 18 researchers and is trusted by 15 researchers here, as inferred from the citation graph.

Subfields

Whom Antoni Ribas trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. Pardoll
  2. C. Robert
  3. J. Wolchok
  4. S. Topalian
  5. S. Spranger
  6. F. Hodi
  7. Taku Okazaki
  8. M. Postow
  9. C. Blank
  10. Guido Kroemer

Who trusts Antoni Ribas overall

  1. Liufu Deng
  2. V. Schirrmacher
  3. C. Robert
  4. H. Liang
  5. J. Haanen
  6. I. Siddiqui
  7. A. Labani-Motlagh
  8. J. Wolchok
  9. A. Marusyk
  10. M. Postow

Papers from Antoni Ribas's perspective

Ordered by how strongly the researchers Antoni Ribas trusts endorse each paper. Same corpus, a different order for every researcher.

  1. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma (New England Journal of Medicine)
  2. Cancer immunoediting: from immunosurveillance to tumor escape (Nature Immunology)
  3. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma (Cell)
  4. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. (Genome Research)
  5. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
  6. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape (Science Translational Medicine)
  7. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data (Cancer Discovery)
  8. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (New England Journal of Medicine)
  9. Pembrolizumab for the treatment of non-small-cell lung cancer. (New England Journal of Medicine)
  10. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data (Annals of Oncology)

Their papers